HY004 / Juventas Cell Therapy 
Welcome,         Profile    Billing    Logout  

3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
HY004 / Juventas Cell Therapy
NCT06005649: Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Not yet recruiting
1/2
80
NA
HY004
Juventas Cell Therapy Ltd.
Non-hodgkin Lymphoma
12/24
09/26
B-ALL, NCT06009107: A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r )

Not yet recruiting
1/2
50
NA
HY004, Cyclophosphamide, Fludarabine Phosphate
Juventas Cell Therapy Ltd.
B-cell Acute Lymphoblastic Leukemia
12/24
12/26
NCT04034446: CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Active, not recruiting
1
2
RoW
CD19-CD22 CAR-T cells
Institute of Hematology & Blood Diseases Hospital, Juventas Cell Therapy Ltd.
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
12/23
12/23

Download Options